000			01393 a2200325 4500
005			20250514234418.0
264		0	_c20051006
008			200510s 0 0 eng d
022			_a0022-3166
024	7		_a10.1093/jn/135.8.2062S _2doi
040			_aNLM _beng _cNLM
100	1		_avan Breemen, Richard B
245	0	0	_aHow do intermediate endpoint markers respond to lycopene in men with prostate cancer or benign prostate hyperplasia? _h[electronic resource]
260			_bThe Journal of nutrition _cAug 2005
300			_a2062S-4S p. _bdigital
500			_aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAnticarcinogenic Agents _xtherapeutic use
650	0	4	_aBiomarkers _xblood
650	0	4	_aCarotenoids _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aLycopene
650	0	4	_aMale
650	0	4	_aPlacebos
650	0	4	_aProstate-Specific Antigen _xblood
650	0	4	_aProstatic Hyperplasia _xblood
650	0	4	_aProstatic Neoplasms _xpathology
650	0	4	_aReproducibility of Results
773	0		_tThe Journal of nutrition _gvol. 135 _gno. 8 _gp. 2062S-4S
856	4	0	_uhttps://doi.org/10.1093/jn/135.8.2062S _zAvailable from publisher's website
999			_c15700295 _d15700295